Long-Term Persistency and Costs Associated With the Use of Iron Chelation Therapies in the Treatment of Sickle Cell Disease Within Medicaid Programs

Journal of Medical Economics - United Kingdom
doi 10.3111/13696998.2012.723081
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Informa Healthcare

Related search

The Effect of Iron Chelation Therapy on Overall Survival in Sickle Cell Disease and Β-Thalassemia: A Systematic Review

American Journal of Hematology
Hematology
2018English

Advances in the Treatment of Sickle Cell Disease

Mayo Clinic Proceedings
Medicine
2018English

Coagulation Abnormalities of Sickle Cell Disease: Relationship With Clinical Outcomes and the Effect of Disease Modifying Therapies

Blood Reviews
OncologyHematology
2016English

Use of Metformin in Patients With Sickle Cell Disease

American Journal of Hematology
Hematology
2018English

High Utilizers of Health Care Resources: Results From the Multicenter Compact Study of Complications in Patients With Sickle Cell Disease and Utilization of Iron Chelation Therapy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Possibility of Leukogenicity Effect of Long Term Use of Hydroxyurea in Sickle Cell Anaemia

Journal of Evolution of Medical and Dental Sciences
2015English

Hepatopulmonary Syndrome Associated With Iron Overload in Sickle Cell Anaemia

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2012English

Patterns of Liver Iron Accumulation in Sickle Cell Disease and Thalassaemia Patients With Iron Overload

European Journal of Haematology
MedicineHematology
2010English

Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease

Advances in Experimental Medicine and Biology
BiochemistryMedicineGeneticsMolecular Biology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy